These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30368587)

  • 21. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
    Melani C; Wilson WH; Roschewski M
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma long non-coding RNAs as biomarkers for bone marrow infiltration and stage in diffuse large B-cell lymphoma.
    Abdelhafiz AS; Nabil R; Ghareeb M; Ibraheem D; Ali A; Elshazly SS; Soliman AM; Bakr YM
    Int J Immunopathol Pharmacol; 2024; 38():3946320241292665. PubMed ID: 39393794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
    Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
    Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.
    Nesic M; Bødker JS; Terp SK; Dybkær K
    Biomed Res Int; 2021; 2021():5585148. PubMed ID: 34307658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
    Ofori K; Bhagat G; Rai AJ
    Br J Clin Pharmacol; 2021 Feb; 87(2):284-294. PubMed ID: 33080045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
    Sun Y; Zhu C; Xu F; Cui S; Guan X
    Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
    Hou Y; Zi J; Liu S; Ge Q; Ge Z
    Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.
    Min J; Zhou H; Jiang S; Yu H
    Med Sci Monit; 2022 Feb; 28():e934106. PubMed ID: 35210388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Lakhotia R; Roschewski M
    Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.
    Sarkozy C; Huet S; Carlton VE; Fabiani B; Delmer A; Jardin F; Delfau-Larue MH; Hacini M; Ribrag V; Guidez S; Faham M; Salles G
    Oncotarget; 2017 Jan; 8(5):8765-8774. PubMed ID: 28060738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
    Fu H; Shen J; Zhou H; Zhang F; Li H; Ma Z; Huang W; Chen L; Chen Y; Liu T
    Eur J Haematol; 2022 Apr; 108(4):298-309. PubMed ID: 34997652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Tumor DNA in Lymphoma.
    Thiruvengadam SK; Zain J
    Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.